Insider Transactions in Q1 2022 at Novo Cure LTD (NVCR)
Insider Transaction List (Q1 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 09
2022
|
Pritesh Shah Chief Growth Officer |
SELL
Open market or private sale
|
Direct |
3,669
-4.22%
|
$260,499
$71.19 P/Share
|
|
Mar 08
2022
|
William F Doyle Executive Chairman |
SELL
Open market or private sale
|
Direct |
2,385
-0.43%
|
$166,950
$70.1 P/Share
|
|
Mar 08
2022
|
Todd Christopher Longsworth General Counsel |
SELL
Open market or private sale
|
Direct |
2,339
-3.61%
|
$163,730
$70.1 P/Share
|
|
Mar 08
2022
|
Ashley Cordova Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
759
-1.23%
|
$53,130
$70.1 P/Share
|
|
Mar 08
2022
|
Wilhelmus Cm Groenhuysen Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
2,923
-1.74%
|
$204,610
$70.1 P/Share
|
|
Mar 08
2022
|
William Patrick Burke Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
1,037
-1.82%
|
$72,590
$70.1 P/Share
|
|
Mar 08
2022
|
Frank X Leonard EVP, Pres., Novocure Oncology |
SELL
Open market or private sale
|
Direct |
744
-0.72%
|
$52,080
$70.1 P/Share
|
|
Mar 08
2022
|
Pritesh Shah Chief Growth Officer |
SELL
Open market or private sale
|
Direct |
2,481
-2.94%
|
$173,670
$70.1 P/Share
|
|
Mar 07
2022
|
Pritesh Shah Chief Growth Officer |
SELL
Open market or private sale
|
Direct |
5,294
-5.9%
|
$365,286
$69.55 P/Share
|
|
Mar 04
2022
|
Frank X Leonard EVP, Pres., Novocure Oncology |
SELL
Open market or private sale
|
Direct |
555
-0.54%
|
$38,850
$70.41 P/Share
|
|
Mar 04
2022
|
Wilhelmus Cm Groenhuysen Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
2,569
-1.51%
|
$179,830
$70.41 P/Share
|
|
Mar 04
2022
|
William Patrick Burke Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
1,026
-1.77%
|
$71,820
$70.41 P/Share
|
|
Mar 04
2022
|
Ely Benaim Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,510
-3.37%
|
$105,700
$70.41 P/Share
|
|
Mar 04
2022
|
Pritesh Shah Chief Growth Officer |
SELL
Open market or private sale
|
Direct |
4,546
-2.44%
|
$322,766
$71.88 P/Share
|
|
Mar 04
2022
|
Ashley Cordova Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
556
-0.89%
|
$38,920
$70.41 P/Share
|
|
Mar 04
2022
|
Todd Christopher Longsworth General Counsel |
SELL
Open market or private sale
|
Direct |
1,973
-2.95%
|
$138,110
$70.41 P/Share
|
|
Mar 03
2022
|
Ashley Cordova Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,040
+3.7%
|
$65,520
$13.53 P/Share
|
|
Mar 03
2022
|
Frank X Leonard EVP, Pres., Novocure Oncology |
SELL
Open market or private sale
|
Direct |
930
-0.89%
|
$68,820
$74.5 P/Share
|
|
Mar 03
2022
|
Frank X Leonard EVP, Pres., Novocure Oncology |
BUY
Grant, award, or other acquisition
|
Direct |
17,371
+14.25%
|
-
|
|
Mar 03
2022
|
Wilhelmus Cm Groenhuysen Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
1,301
-0.76%
|
$96,274
$74.5 P/Share
|
|
Mar 03
2022
|
Wilhelmus Cm Groenhuysen Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
21,921
+11.31%
|
-
|
|
Mar 03
2022
|
William Patrick Burke Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
341
-0.58%
|
$25,234
$74.5 P/Share
|
|
Mar 03
2022
|
William Patrick Burke Chief Human Resources Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,445
+11.31%
|
-
|
|
Mar 03
2022
|
Ely Benaim Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
803
-1.76%
|
$59,422
$74.5 P/Share
|
|
Mar 03
2022
|
Ely Benaim Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,371
+27.6%
|
-
|
|
Mar 03
2022
|
Pritesh Shah Chief Growth Officer |
SELL
Open market or private sale
|
Direct |
997
-1.05%
|
$73,778
$74.5 P/Share
|
|
Mar 03
2022
|
Pritesh Shah Chief Growth Officer |
BUY
Grant, award, or other acquisition
|
Direct |
21,714
+18.57%
|
-
|
|
Mar 03
2022
|
Uri Weinberg Chief Innovation Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,371
+26.1%
|
-
|
|
Mar 03
2022
|
Ashley Cordova Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,149
-1.81%
|
$85,026
$74.5 P/Share
|
|
Mar 03
2022
|
Ashley Cordova Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
21,508
+25.36%
|
-
|
|
Mar 03
2022
|
Todd Christopher Longsworth General Counsel |
SELL
Open market or private sale
|
Direct |
1,094
-1.61%
|
$80,956
$74.5 P/Share
|
|
Jan 06
2022
|
Wilhelmus Cm Groenhuysen Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
75
+0.05%
|
$4,725
$63.82 P/Share
|
|
Jan 06
2022
|
Asaf Danziger Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
31
+0.23%
|
$1,953
$63.82 P/Share
|
|
Jan 06
2022
|
Ashley Cordova Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
46
+0.11%
|
$2,898
$63.82 P/Share
|
|
Jan 06
2022
|
Ely Benaim Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
55
+0.19%
|
$3,465
$63.82 P/Share
|
|
Jan 06
2022
|
William Patrick Burke Chief Human Resources Officer |
BUY
Grant, award, or other acquisition
|
Direct |
80
+0.16%
|
$5,040
$63.82 P/Share
|
|
Jan 06
2022
|
Uri Weinberg Chief Innovation Officer |
BUY
Grant, award, or other acquisition
|
Direct |
35
+0.11%
|
$2,205
$63.82 P/Share
|
|
Jan 03
2022
|
William Patrick Burke Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
3,951
-2.87%
|
$300,276
$76.03 P/Share
|
|
Jan 03
2022
|
William Patrick Burke Chief Human Resources Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
28,604
+15.77%
|
$371,852
$13.4 P/Share
|